PRC
MLTX icon

Pearl River Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Pearl River Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,067
Closed -$355K – 228
2024
Q2 		$355K Buy
8,067
+1,317
+20% +$55.8K 0.06% 333
2024
Q1 		$339K Buy
6,750
+2,458
+57% +$133K 0.05% 370
2023
Q4 		$259K Buy
+4,292
New +$221K 0.04% 423

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Pearl River Capital's MLTX Position: Q3 2024 in Review

Pearl River Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2024, closing a stake of 8,067 shares — an estimated $355K sold.

Pearl River Capital first reported a position in MLTX in Q4 2023 and held it in 3 quarters. The position peaked at $355K in Q2 2024. 109 funds tracked by Wall St. Rank hold MLTX as of Q3 2024.

  • Pearl River Capital reported no remaining MoonLake Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Pearl River Capital sold 8,067 MoonLake Immunotherapeutics shares in Q3 2024, an estimated $355K.
  • Pearl River Capital first reported a position in MoonLake Immunotherapeutics in Q4 2023 and held it in 3 quarters.
  • Pearl River Capital's MoonLake Immunotherapeutics position peaked at $355K in Q2 2024.
  • 109 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2024.

Based on Pearl River Capital's 13F filing for Q3 2024.